Multi-Dose Pen Injectors for Cardiometabolic Therapies Market
完整報告名稱與涵蓋範圍
Multi-Dose Pen Injectors for Cardiometabolic Therapies Market Size, Share & Trends Analysis Report, By Device Type (Disposable Prefilled Multi-Dose Pens, Reusable Multi-Dose Pens, Connected and Smart Pens), By Therapy (GLP-1 and Incretin-Based Therapies, Insulin, Lipid-Lowering and Other Cardiometabolic Injectables), By Dose Mechanism (Fixed-Dose Pens, Variable-Dose Dial Pens), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The multi-dose pen injectors for cardiometabolic therapies market covers disposable prefilled, reusable and connected pen injectors that deliver multiple doses of GLP-1 and incretin-based therapies, insulin and other injectable cardiometabolic drugs, together with the pen platforms and components supplied to pharmaceutical companies. Single-dose autoinjectors, wearable injectors and pens for non-cardiometabolic therapies such as growth hormone are excluded, and cartridge-based autoinjectors are addressed in a separate InsightAce study.
Pen injectors are the dominant delivery format for insulin and for weekly and daily incretin therapies, and demand has been reshaped by the obesity and diabetes incretin boom, which strained pen manufacturing capacity and prompted originators and platform companies to invest in new assembly lines and dual sourcing. Growth is supported by expanding insulin and incretin use in emerging markets, biosimilar and generic entrants adopting proven pen platforms and connected pens that log doses and integrate with glucose monitoring and coaching apps. Device makers compete on dose accuracy, injection force, needle technology, sustainability of disposable pens and connectivity, while pharmaceutical companies balance proprietary platforms against licensed devices and pursue reusable designs to cut waste.
North America and Europe generate most value, while China, India and Latin America drive volume growth through insulin and generic incretin adoption. Competition involves the incretin and insulin originators with in-house devices, Swiss and European platform companies and Asian device manufacturers.
The InsightAce study supplies US$ forecasts for all device type, therapy, dose mechanism and end user and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Multi-Dose Pen Injectors for Cardiometabolic Therapies Market Snapshot
Chapter 4. Global Multi-Dose Pen Injectors for Cardiometabolic Therapies Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Device Type Estimates & Trend Analysis
5.1. Device Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Device Type:
5.2.1. Disposable Prefilled Multi-Dose Pens
5.2.2. Reusable Multi-Dose Pens
5.2.3. Connected and Smart Pens
Chapter 6. Market Segmentation 2: By Therapy Estimates & Trend Analysis
6.1. Therapy & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Therapy:
6.2.1. GLP-1 and Incretin-Based Therapies
6.2.2. Insulin
6.2.3. Lipid-Lowering and Other Cardiometabolic Injectables
Chapter 7. Market Segmentation 3: By Dose Mechanism Estimates & Trend Analysis
7.1. Dose Mechanism & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Dose Mechanism:
7.2.1. Fixed-Dose Pens
7.2.2. Variable-Dose Dial Pens
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Pharmaceutical Companies
8.2.2. Home Users and Patients
8.2.3. Hospitals and Clinics
Chapter 9. Multi-Dose Pen Injectors for Cardiometabolic Therapies Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Novo Nordisk A/S
11.2. Eli Lilly and Company
11.3. Sanofi
11.4. Ypsomed AG
11.5. SHL Medical AG
11.6. Becton, Dickinson and Company
11.7. Haselmeier (medmix AG)
11.8. Owen Mumford Ltd.
11.9. Nemera
11.10. Gerresheimer AG
11.11. Stevanato Group S.p.A.
11.12. Phillips-Medisize (Molex, Koch Industries)
11.13. Biocon Biologics Ltd.
11.14. Jiangsu Delfu Medical Device Co., Ltd.
11.15. Embecta Corp.
圖表清單 List of Tables & Figures
Table 1. Global Multi-Dose Pen Injectors for Cardiometabolic Therapies Market Revenue Forecast by Device Type, 2026-2035 (US$ Mn)
Figure 1. Global Multi-Dose Pen Injectors for Cardiometabolic Therapies Market Segmentation and Scope Overview
Table 2. Global Multi-Dose Pen Injectors for Cardiometabolic Therapies Market Revenue Forecast by Therapy, 2026-2035 (US$ Mn)
Figure 2. Global Multi-Dose Pen Injectors for Cardiometabolic Therapies Market Share by Device Type, 2026 & 2035
Table 3. Global Multi-Dose Pen Injectors for Cardiometabolic Therapies Market Revenue Forecast by Dose Mechanism, 2026-2035 (US$ Mn)
Figure 3. Pen Injector Demand by Therapy and Device Type as Incretin and Insulin Use Expands, 2026-2035
Table 4. Global Multi-Dose Pen Injectors for Cardiometabolic Therapies Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Pen Manufacturing Capacity Expansion and Dual-Sourcing Strategies, 2024-2030
Table 5. Global Multi-Dose Pen Injectors for Cardiometabolic Therapies Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Multi-Dose Pen Injectors for Cardiometabolic Therapies Growth Opportunity Analysis
Table 6. North America Multi-Dose Pen Injectors for Cardiometabolic Therapies Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key Multi-Dose Pen Injectors for Cardiometabolic Therapies Market Participants
Table 7. Europe Multi-Dose Pen Injectors for Cardiometabolic Therapies Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global Multi-Dose Pen Injectors for Cardiometabolic Therapies Market
Table 8. Asia Pacific Multi-Dose Pen Injectors for Cardiometabolic Therapies Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Connected Pen Adoption and Integration with Glucose Monitoring and Digital Coaching
Table 9. Strategic Developments of Leading Multi-Dose Pen Injectors for Cardiometabolic Therapies Market Participants, 2023-2026
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們